Dogwood Therapeutics director granted 16,800 stock options

Dogwood Therapeutics director David R. Keefer received a new stock option grant for 16,800 shares of common stock.

Rhea-AI Filing Summary

Dogwood Therapeutics director David R. Keefer received a new stock option grant for 16,800 shares of common stock. The options have an exercise price of $1.50 per share, allowing him to buy shares at that price in the future. Following this grant, he holds 16,800 options directly. The options become exercisable starting June 16, 2027 and expire on June 16, 2036, making this a long-term, compensation-related award rather than an open-market trade.

Insider Trade Summary

Grant/Award: 16,800 shares

Grant/Award 1 txn

Insider Keefer David R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	16,800	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 16,800 contracts (Direct)

Key Figures

Option grant size: 16,800 shares Exercise price: $1.50 per share Total options after grant: 16,800 options +2 more

5 metrics

Option grant size 16,800 shares Stock Option (right to buy) grant to director Keefer

Exercise price $1.50 per share Conversion or exercise price of the stock option

Total options after grant 16,800 options Total derivative shares following transaction, direct ownership

Exercise start date June 16, 2027 Option exercise date

Expiration date June 16, 2036 Option expiration date

Key Terms

Stock Option (right to buy), exercise price, grant/award acquisition, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.5000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

grant/award acquisition financial

"transaction_action: grant/award acquisition"

expiration date financial

"expiration_date: 2036-06-16T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dogwood Therapeutics (DWTX) director David R. Keefer report on this Form 4?

David R. Keefer reported receiving a stock option grant for 16,800 shares of Dogwood Therapeutics common stock. This is a compensation-related award, not an open-market trade, and gives him the right to buy shares at a fixed exercise price.

How many Dogwood Therapeutics (DWTX) options were granted to David R. Keefer?

He was granted stock options covering 16,800 shares of Dogwood Therapeutics common stock. These options increase his potential equity exposure and represent his total reported derivative holdings following the transaction, according to the Form 4 data provided.

What is the exercise price of David R. Keefer’s Dogwood Therapeutics (DWTX) options?

The stock options have an exercise price of $1.50 per share. This means he can purchase Dogwood Therapeutics common stock at $1.50 per share once the options become exercisable, regardless of the market price at that time.

When can David R. Keefer exercise his Dogwood Therapeutics (DWTX) stock options?

The options become exercisable on June 16, 2027. From that date until their expiration, he can choose to exercise them and buy Dogwood Therapeutics common stock at the fixed $1.50 per-share exercise price.

When do David R. Keefer’s Dogwood Therapeutics (DWTX) options expire?

The stock options expire on June 16, 2036. After that expiration date, any unexercised portion of the 16,800-share grant will lapse, and he will no longer have the right to purchase those shares at $1.50.

Is this Dogwood Therapeutics (DWTX) Form 4 a buy or sell transaction in the market?

This Form 4 reports a grant of stock options, not a market buy or sell. It is classified as a grant or award acquisition, providing compensation through options rather than reflecting an open-market stock purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 01:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keefer David R

(Last) (First) (Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA GEORGIA 30009

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.5	06/16/2026		A		16,800		06/16/2027	06/16/2036	Common Stock	16,800	$0	16,800	D

Explanation of Responses:

	/s/ Greg Duncan, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)